Publikation

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer

Wissenschaftlicher Artikel/Review - 17.02.2014

de Bono Johann S, Scranton Judith, Wang Tao, Hudes Gary R, Gillessen Sommer Silke, Fong Peter, Sandhu Shahneen K, Aparicio Luis Miguel A, Saad Fred, Petrylak Daniel P, Pandha Hardev S, Piulats Josep M, Pollak Michael N